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Randomized, Controlled, Phase 2 Trial of
Povidone-Iodine/Dexamethasone Ophthalmic
Suspension for Treatment of Adenoviral
Conjunctivitis
JAY S. PEPOSE, ARJUN AHUJA, WENLEI LIU, ABHIJIT NARVEKAR, AND REZA HAQUE
 PURPOSE: To evaluate the efficacy/safety of an
ophthalmic suspension of povidone-iodine (PVP-I)
0.6% and dexamethasone 0.1% in patients with acute
adenoviral conjunctivitis.
 DESIGN: Multicenter, randomized, vehicle-controlled,
double-masked trial.
 METHODS: Adults with a positive Rapid Pathogen
Screening Adeno-Detector Plus test were randomized
1:1:1 to PVP-I 0.6%/dexamethasone 0.1%, PVP-I
0.6%, or vehicle, bilaterally 4 times daily for 5 days
(days 1-5). Patients were evaluated on days 3, 6, and 12
(D1-day window). Efficacy measures included clinical
resolution and adenoviral eradication.
 RESULTS: Overall, 144 patients were included in the
efficacy analysis (PVP-I/dexamethasone, n [ 48; PVP-
I, n[ 50; vehicle, n[ 46). The proportion of patients
with clinical resolution (primary study eye with last
observation carried forward [LOCF]) at the day 6 visit
was higher with PVP-I/dexamethasone (31.3%) than
with vehicle (10.9%; P [ .0158) and PVP-I (18.0%;
P [ nonsignificant). The proportion with adenoviral
eradication (primary study eye with LOCF) was higher
with PVP-I/dexamethasone than with vehicle at the day
3 (35.4% vs 8.7%; P [ .0019) and day 6 (79.2% vs
56.5%; P [ .0186) visits and vs PVP-I (day 3 visit,
32.0%; day 6 visit, 62.0%; each P [ nonsignificant).
Treatment-emergent adverse events (AEs) occurred in
69.0% (vehicle), 62.7% (PVP-I), and 53.4% (PVP-I/
dexamethasone) of patients in the safety dataset. Discon-
tinuation owing to AEs occurred in 37 patients (vehicle,
n[ 16; PVP-I, n[ 12; PVP-I/dexamethasone, n[ 9).
 CONCLUSION: PVP-I/dexamethasone appeared safe
and well tolerated, and significantly improved clinical
resolution and adenoviral eradication in patients with
acute adenoviral conjunctivitis. (Am J Ophthalmol
2018;194:7–15.  2018 Shire, Lexington, MA, USA.
Published by Elsevier Inc. This is an open access article
under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).)
A
CUTE CONJUNCTIVITIS IS A COMMON CONDITION,
estimated to affect approximately 6 million people
each year in the United States.1 Viruses and bacte-
ria are the most common pathogens associated with acute
infectious conjunctivitis, with adenoviruses considered to
be the most frequent cause of viral conjunctivitis.2 Adeno-
viral conjunctivitis can cause significant discomfort and
lost productivity. Although mostly self-limiting, in some
cases it can lead to complications from long-term
immune-mediated sequelae.3 Adenoviruses are nonenvel-
oped viruses that are relatively resistant to disinfection,4
and adenoviral conjunctivitis is more contagious than
other forms of conjunctivitis owing in part to adenoviruses
being able to survive in a desiccated state for several weeks
at room temperature.5
No medications are currently approved for the treatment
of adenoviral conjunctivitis, and treatment is mostly
supportive. A novel topical ophthalmic suspension of
povidone-iodine (PVP-I) 0.6% and dexamethasone 0.1%
is under clinical investigation, and has the potential to treat
both the viral and inflammatory components of adenoviral
conjunctivitis as well as immune-related sequelae such as
subepithelial infiltrates. Dexamethasone is a potent, well-
tolerated corticosteroid6,7 routinely used as a topical
ophthalmic antiinflammatory agent.8,9 PVP-I is an anti-
septic used in ophthalmology and general surgery.10–12
The combination of PVP-I and dexamethasone in
various formulations has been studied in several preclinical
and early-stage clinical trials. These include a study using a
rabbit model of adenoviral keratoconjunctivitis, in which
treatment with PVP-I 0.4%/dexamethasone 0.1% resulted
in significantly improved clinical scores and significantly
reduced viral titers compared with control treatments.13
In an open-label trial of 6 patients with acute conjunctivitis
who were positive for adenovirus by the Rapid Pathogen
Screening Adeno-Detector test, clinical resolution and
reduction of viral titer occurred within 5 days of treatment
with PVP-I 0.4%/dexamethasone 0.1% 4 times daily
(QID).14 In a randomized controlled trial of 122 patients
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with a clinical diagnosis of presumed viral conjunctivitis,
ocular administration of PVP-I 0.4%/dexamethasone
0.1% QID significantly reduced the duration of conjuncti-
vitis compared with patients receiving artificial tears.15
More recently, in a randomized controlled trial of 74
patients with adenoviral keratoconjunctivitis, patients
treated with PVP-I 1.0%/dexamethasone 0.1%
experienced significantly faster improvement of clinical
signs than control groups, with near-complete recovery in
5-7 days and almost-complete viral eradication (92%
reduction) by the fifth day of treatment.16
In this multicenter phase 2 randomized controlled study,
we evaluated the efficacy and safety of an ophthalmic
suspension of PVP-I 0.6% and dexamethasone 0.1% for
the treatment of acute adenoviral conjunctivitis in adults.
METHODS
 STUDY DESIGN: This was a multicenter, randomized,
double-masked, parallel-group, active- and vehicle-
controlled phase 2 study conducted in India. Patients
were randomized 1:1:1 to PVP-I 0.6%/dexamethasone
0.1% ophthalmic suspension, PVP-I 0.6% alone, or
vehicle. One drop of study medication was applied to
each eye QID for 5 days. The first dose was administered
in the office on day 1 (visit 1), with office visits for efficacy
and safety evaluations on day 3 (visit 2), day 6 (visit 3), and
day 12 (visit 4), with a þ1-day window allowed (Figure 1).
The study treatments were provided as sterile, preserved
suspensions or solutions in 10-mL amber glass bottles
with separate sterile dropper tips for topical ophthalmic
administration. Compliance with treatment was assessed
by review of dosing diaries provided to the patients. Any
patient who missed >20% of doses during a given dosing
period was considered noncompliant during that dosing
period.
The study was performed in compliance with the ethical
principles of the Declaration of Helsinki andGood Clinical
Practice. The trial protocol and its amendments, informed
consent form, and subject diary instructions were approved
by ethics committees at all participating sites prior to study
initiation; a list of the independent ethics committees can
be found at Clinical Trials Registry India (http://ctri.nic.in/
Clinicaltrials/login.php) using the trial search keyword
‘‘FST100.’’ All patients provided written informed consent.
The trial was registered at ClinicalTrials.gov (identifier
NCT01470664).
 PATIENTS: All patients were recruited from eye clinics
in India. Eligible patients were adults (>_18 years) who
had a best-corrected visual acuity (BCVA) of 0.60
logarithm of the minimum angle of resolution (logMAR)
or better in each eye. In addition, patients were required
to have signs of adenoviral conjunctivitis within 5 days of
visit 1, a positive Rapid Pathogen Screening Adeno-
Detector Plus test (Rapid Pathogen Screening Inc, Sara-
sota, Florida, USA) at visit 1, a diagnosis of suspected acute
adenoviral conjunctivitis in >_1 eye, and a watery conjunc-
tival discharge score of >_1 and bulbar conjunctival redness
score of >_1 (both on a 0-3 scale, where 0 ¼ absent/normal,
1 ¼ mild, 2 ¼ moderate, and 3 ¼ severe).
Exclusion criteria included pregnancy or nursing; known
sensitivity to any of the components of the investigational
drugs; presence of an ocular infection or inflammation other
than acute adenoviral conjunctivitis; intraocular pressure
(IOP) steroid responders or those with a history of glaucoma
or elevated IOP> 21mmHg; or history of recurrent corneal
erosion syndrome or those with clinically significant optic
nerve defects, active ulcerative keratitis, autoimmune
disease, uncontrolled systemic disease, or debilitating dis-
ease. Use of contact lenses, investigational devices, and
the followingmedications were prohibited during the study:
antivirals, corticosteroids (except for stable use of inhaled/
nasal corticosteroids and topical steroids [not including
around the eye]), or any other topical ophthalmic solutions
(including investigational or diagnostic products).
 EFFICACY ASSESSMENTS: The following efficacy
endpoints were included: (1) a composite endpoint of
clinical resolution (absence [score ¼ 0] of watery conjunc-
tival discharge and bulbar conjunctival redness) and
adenoviral eradication (negative cell culture immunofluo-
rescence assay [CC-IFA]) in the study eye; (2) the individ-
ual measurement of clinical resolution or adenoviral
eradication; (3) expanded clinical cure (both watery
conjunctival discharge and bulbar conjunctival redness
scores of 0 or 1); and (4) global clinical score (sum of
bulbar conjunctival redness and watery conjunctival
discharge scores, total score 0-6). Crossover infection was
also recorded, based on an increase in the global clinical
score of the fellow eye, where the fellow eye was defined
according to the clinically worse study eye definition (see
Statistical Analyses). All fellow eyes were eligible for
assessment of crossover infection, regardless of the global
clinical score at baseline.
 SAFETYASSESSMENTS: Safety was the primary endpoint of
this trial. Safety measures included slit-lamp biomicroscopy
(including nondilated fundus examination), BCVA, urine
pregnancy test, and adverse events (AEs). Tolerability was
Screening Randomization Treatment (days 1–5)
Visit 1 (day 1) Visit 2 (day 3+1) Visit 3 (day 6+1) Visit 4 (day 12+1)
PVP-I/dexamethasone
PVP-I
Vehicle
Follow-up/
Exit visit
FIGURE 1. Study design. PVP-I[ povidone-iodine.
8 OCTOBER 2018AMERICAN JOURNAL OF OPHTHALMOLOGY
measured by assessment of drop comfort at the day 1 visit by
the patient upon instillation (administered by a designated
staff member), and at 1 and 2 minutes after instillation using
a 0-10 scale (0¼ very comfortable, 10¼ very uncomfortable).
IOP was not measured during the study.
 STATISTICAL ANALYSES: The efficacy analysis was
conducted on the modified intent-to-treat (mITT)
population, a subset of the ITT population (randomized pa-
tients who received >_1 dose of study medication) who had
positive CC-IFA results in >_1 eye at day 1, watery conjunc-
tival discharge and bulbar conjunctival redness scores >_1 in
the same eye at day 1, and >_1 follow-up visit. All analyses
except crossover infection were conducted using the pri-
mary study eye, defined as the eye with a positive CC-
IFA at day 1 or, if both/neither were infected, the eye
Randomized (n=176)
Allocated to PVP-I/
dexamethasone (n=59)
• Received allocated 
 intervention (n=58)
• Did not receive allocated 
 intervention (n=1)a
Allocated to PVP-I (n=59)
• Received allocated
 intervention (n=59)
Allocated to vehicle (n=58)
• Received allocated
 intervention (n=58)
Discontinued the study (n=13)
• Adverse events (n=9) 
• Subject’s decision (n=2)
• Administrative reasons
 (n=2)
Discontinued the study (n=15)
• Adverse events (n=12)
• Subject’s decision (n=2)
• Administrative reasons
 (n=1)
Discontinued the study (n=24)
• Adverse events (n=16)
• Lack of efficacy (n=2)
• Subject’s decision (n=6)
Completed study (n=46)
ITT population (n=58)
Modified ITT population (n=48)
Safety population (n=58)
Completed study (n=44)
ITT population (n=59)
Modified ITT population (n=50)
Safety population (n=59)
Completed (n=34)
ITT population (n=58)
Modified ITT population (n=46)
Safety population (n=58)
FIGURE 2. Patient disposition. aOne patient was randomized but did not receive study treatment; this patient discontinued at visit 1
(subject decision) and was excluded from all analysis populations. ITT[ intent-to-treat; PVP-I[ povidone-iodine.
TABLE 1. Demographic Characteristics (Intent-to-Treat Population)
PVP-I/Dexamethasone
N ¼ 58
PVP-I
N ¼ 59
Vehicle
N ¼ 58
All Patients
N ¼ 175
Age, mean (SD), years 33.7 (12.3) 35.1 (11.0) 34.6 (13.3) 34.5 (12.2)
Sex, n (%)
Male 39 (67.2) 40 (67.8) 37 (63.8) 116 (66.3)
Female 19 (32.8) 19 (32.2) 21 (36.2) 59 (33.7)
Race, n (%)
Asian 58 (100) 59 (100) 58 (100) 175 (100)
PVP-I ¼ povidone-iodine.
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with the highest global clinical score. If both eyes had the
same score, the right eye was the study eye. Analysis of the
crossover infection data was conducted using the clinically
worse study eye definition (eye with the highest global clin-
ical score at baseline or, if both eyes had the same global
clinical score at baseline, the right eye). The nonstudy
eye was designated as the fellow eye.
Binary efficacy endpoints were compared between treat-
ment arms using Pearson x2 or Fisher exact tests (in the case
of expected counts< 5); change from baseline in global clin-
ical score and raw score were compared between treatment
arms using the 2-sample t test, at the 2-sided .05 significance
levelwithmissing data imputed by last observation carried for-
ward (LOCF). Formal sample size calculations were not
performed, as this trial was a proof-of-concept study.However,
a sample size of 160 evaluable patients (approximately 53-54
per treatment arm) was deemed reasonable to assess safety
and provide information for powering future studies.
RESULTS
 STUDYPOPULATION: The study was conducted between
December 17, 2012 and May 23, 2014. A total of 176 pa-
tients were randomized, and 124 completed the study
(Figure 2). The safety and ITT populations included 175
patients. The mITT population included 144 patients.
The mean (standard deviation) age across all patients in
the ITT population was 34.5 (12.2) years. Two thirds of pa-
tients were male (66.3%) and all were Asian (Table 1).
Three patients in the vehicle group and 1 patient in the
PVP-I/dexamethasone group were recorded as noncompli-
ant with dosing.
Serotype data were available for 18 patients (6 in the
PVP-I/dexamethasone group, 5 in the PVP-I group, and 7
in the vehicle group), most of whom had serotype data
across multiple visits. Of these, 17 patients had the D8
serotype in both eyes. At visits 1 and 2, 1 patient in the
vehicle arm had the B3 serotype in the fellow eye and
the D8 serotype in the study eye.
 CLINICAL RESOLUTION: After 5 days of treatment (day 6
visit), the proportion of patients with clinical resolution in
the primary study eye was significantly higher in the PVP-
I/dexamethasone group (31.3% [15/48]) compared with the
vehicle group (10.9% [5/46], P ¼ .0158), and numerically
higher compared with the PVP-I group (18.0% [9/50], P ¼
nonsignificant [NS]) (Figure 3). At the day 6 visit, a greater
proportion of patients also had complete resolution of the in-
dividual signs with PVP-I/dexamethasone compared with
vehicle (P ¼ .0056 for discharge, P ¼ .0202 for redness) or
Clinical Resolution
0
20
40
60
80
PVP-I/dexamethasone
PVP-I
Vehicle
P=.0158 P=.0202
P=.0056
P=.0266
31.3
18.0
10.9
54.2
32.0
26.1
33.3
18.0
13.0
Bulbar Conjunctival
Redness Score=0
Watery Conjunctival
Discharge Score=0
P
at
ie
nt
s,
 %
FIGURE 3. Clinical resolution, watery conjunctival discharge, and bulbar conjunctival redness at day 6 (D1-day window; modified
intent-to-treat population with last observation carried forward, primary study eye). Clinical resolution was defined as the absence
(score [ 0) of both watery conjunctival discharge and bulbar conjunctival redness. Watery conjunctival discharge and bulbar
conjunctival redness were scored on a scale of 0 (absent/normal) to 3 (severe). Only statistically significant P values (< .05) are
shown; all other comparisons between treatment groups were nonsignificant. PVP-I[ povidone-iodine.
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PVP-I (P¼ .0266 for discharge, P¼NS for redness). No pa-
tients had clinical resolution at the day 3 visit. By the day 12
visit, 62.5% of patients (30/48) treated with PVP-I/
dexamethasone, 62.0% (31/50) treated with PVP-I, and
45.7% (21/46) treated with vehicle had clinical resolution
(P ¼ NS between treatment groups).
 ADENOVIRAL ERADICATION: After 5 days of treatment
(day 6 visit), the proportion of patients with adenoviral
eradication in the primary study eye was significantly
greater following treatment with PVP-I/dexamethasone
(79.2% [38/48]) compared with vehicle (56.5% [26/46],
P ¼ .0186), and numerically greater compared with PVP-
I (62.0% [31/50], P ¼ NS) (Figure 4). Adenoviral eradica-
tion with PVP-I/dexamethasone was evident as early as at
the day 3 visit, and remained statistically significantly
greater compared with vehicle at the day 12 visit.
The proportion of patients at the day 6 visit with both
adenoviral eradication and clinical resolution was signifi-
cantly greater in the PVP-I/dexamethasone group (31.3%
[15/48]) than in the vehicle group (6.5% [3/46];
P ¼ .0023), and numerically greater than in the PVP-I
group (18.0% [9/50], P ¼ NS) (Figure 5).
 EXPANDED CLINICAL CURE: The proportion of patients
achieving expanded clinical cure with PVP-I/
dexamethasone was significantly greater compared with
vehicle at all visits (day 3 visit, 35.4% [17/48] vs 8.7% [4/
46], P ¼ .0019; day 6 visit, 77.1% [37/48] vs 43.5% [20/46],
P ¼ .0009; day 12 visit, 95.8% [46/48] vs 71.7% [33/46],
P ¼ .0014), and compared with PVP-I at the day 6 visit
(77.1% [37/48] vs 52.0% [26/50],P¼ .0096). The proportion
of patients with expanded clinical cure was also numerically
greater following treatment with PVP-I/dexamethasone
than with PVP-I at the day 3 visit (35.4% [17/48] vs 18.0%
[9/50], P ¼ NS) and day 12 visit (95.8% [46/48] vs 84.0%
[42/50], P¼NS). The proportion of patients with expanded
clinical cure in the PVP-I group was not significantly
different from that in the vehicle group at all visits.
 GLOBAL CLINICAL SCORE: Reductions from baseline in
the global clinical score were significantly greater following
treatment with PVP-I/dexamethasone compared with
vehicle at all visits (mean change from baseline: day 3 visit,
–1.7 vs –0.9, P ¼ .0097; day 6 visit, –3.6 vs –2.1, P ¼ .0002;
day 12 visit, –4.3 vs –3.5,P¼ .0468), and at the day 3 and day
6 visits compared with PVP-I (day 3 visit, –1.7 vs –1.1,
P ¼ .0370; day 6 visit, –3.6 vs –2.6, P ¼ .0057; day 12 visit,
–4.3 vs –4.1, P ¼ NS). The proportion of patients in the
PVP-I/dexamethasone group with any improvement from
baseline in global clinical score was significantly greater
than with vehicle at all visits (day 3 visit, 81.3% vs 56.5%,
P ¼ .0095; day 6 visit, 97.9% vs 76.1%, P ¼ .0015; day 12
visit, 100% vs 87.0%, P ¼ .0115), and significantly greater
than PVP-I at the day 3 (81.3% vs 60.0%, P ¼ .0212) and
day 6 (97.9% vs 82.0%, P ¼ .0158) visits.
At all visits, compared with vehicle, a significantly greater
proportion of patients in the PVP-I/dexamethasone group
0
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Day 3+1
(Visit 2)
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(Visit 3)
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P=.0056
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P=.0050
FIGURE 4. Adenoviral eradication at days 3, 6, and 12 (D1-day window; modified intent-to-treat population with last observation
carried forward, primary study eye). Adenoviral eradication was defined as a negative cell culture immunofluorescence assay result.
Only statistically significant P values (< .05) are shown; all other comparisons between treatment groups were nonsignificant.
PVP-I[ povidone-iodine.
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had either a >_2-point reduction from baseline in the global
clinical score (day 3 visit, 70.8% vs 39.1%, P ¼ .002; day 6
visit, 91.7% vs 58.7%, P ¼ .0002; day 12 visit, 100% vs
76.1%, P ¼ .0003) or a >_50% reduction (day 3 visit, 39.6%
vs 6.5%, P ¼ .0002; day 6 visit, 85.4% vs 43.5%, P <.0001;
day 12 visit, 97.9% vs 71.7%, P ¼ .0004). The reduction
from baseline in global clinical score in the PVP-I/
dexamethasone arm was also statistically superior to that in
the PVP-I arm at the day 3 and day 6 visits for both a >_2-
point reduction (day 3 visit, 70.8% vs 48.0%, P ¼ .0215;
day 6 visit, 91.7% vs 70.0%, P ¼ .0067) and a >_50% reduc-
tion (day 3 visit, 39.6% vs 20.0%, P ¼ .0337; day 6 visit,
85.4%vs 58.0%,P¼ .0027).At the day 6 visit, a significantly
greater proportion of patients in the PVP-I/dexamethasone
group, compared with vehicle or PVP-I alone, had a >_3-
point reduction (75.0% vs 43.5%, P ¼ .0019 vs vehicle;
75.0% vs 54.0%, P¼ .0301 vs PVP-I) or >_4-point reduction
(58.3% vs 28.3%, P¼ .0033 vs vehicle; 58.3% vs 34.0%, P¼
.0157 vs PVP-I) from baseline. At all visits, none of the
global clinical score endpoints in the PVP-I group were
significantly different from those in the vehicle group.
 CROSSOVER INFECTION: The majority of patients in
each treatment group did not meet the definition of cross-
over infection at each visit (Table 2).
 SAFETY: Overall, 61.7% of patients (108/175) experi-
enced 281 treatment-emergent AEs (TEAEs). The propor-
tion of patients with TEAEs was highest in the vehicle
group (69.0% [40/58]), followed by the PVP-I group
(62.7% [37/59]) and the PVP-I/dexamethasone group
(53.4% [31/58]). The majority of TEAEs were mild in
severity, no serious AEs were reported, and no TEAEs
were suspected of being related to study treatment.
Thirty-seven patients withdrew owing to AEs (PVP-I/
dexamethasone, n ¼ 9/58 [15.5%]; PVP-I, n ¼ 12/59
[20.3%]; vehicle, n ¼ 16/58 [27.6%]). The majority of
TEAEs were ocular, with only 3 nonocular TEAEs reported
by 2 patients (headache reported by 1 PVP-I-treated pa-
tient, and nasopharyngitis and cough reported by 1
vehicle-treated patient). The most frequently reported
0
20
40
60
80 PVP-I/dexamethasone
PVP-I
Vehicle
31.3
18.0
6.5
60.4 58.0
41.3
Treated days 1–5 Exit visit
P
at
ie
nt
s,
 %
P=.0023
Day 12+1
(Visit 4)
Day 6+1
(Visit 3)
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FIGURE 5. Both adenoviral eradication and clinical resolution at days 3, 6, and 12 (D1-day window; modified intent-to-treat pop-
ulation with last observation carried forward, primary study eye). Adenoviral eradication was defined as a negative cell culture immu-
nofluorescence assay result. Clinical resolution was defined as the absence (score [ 0) of both watery conjunctival discharge and
bulbar conjunctival redness. Only statistically significant P values (< .05) are shown; all other comparisons between treatment
groups were nonsignificant. PVP-I[ povidone-iodine.
TABLE 2. Crossover Infection (Intent-to-Treat Population
With Last Observation Carried Forward)
PVP-I/Dexamethasone
N ¼ 58
PVP-I
N ¼ 59
Vehicle
N ¼ 58
Visit 2 7 (12.1) 17 (28.8) 9 (15.5)
Visit 3 11 (19.0) 16 (27.1) 15 (25.9)
Visit 4 9 (15.5) 7 (11.9) 8 (13.8)
PVP-I ¼ povidone-iodine.
Values are n (%).
Crossover infection to a patient’s fellow eye was a binary var-
iable (yes/no) based on an increase in the global clinical score
(sum of watery conjunctival discharge and bulbar conjunctival
redness) in the fellow eye.
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ocular TEAEs were corneal infiltrates, punctate keratitis,
eyelid edema, and conjunctivitis. Most events occurred
more frequently in the PVP-I and vehicle groups than in
the PVP-I/dexamethasone group (Table 3).
There were no safety concerns raised in any of the clin-
ical examinations (including BCVA and slit-lamp bio-
microscopy). Mean drop comfort scores upon instillation
were similar among all treatment groups and were 2 or 3
on a scale from 0 (very comfortable) to 10 (very uncomfort-
able).
DISCUSSION
THE RESULTS OF THIS STUDY INDICATE THAT AN
ophthalmic suspension of PVP-I 0.6% and dexamethasone
0.1% is safe and well tolerated for the treatment of acute
adenoviral conjunctivitis. Outcomes for PVP-I 0.6%/dexa-
methasone 0.1% showed statistical superiority compared
with vehicle for clinical resolution, adenoviral eradication,
expanded clinical cure, and multiple parameters of global
clinical score. Trends to improvement relative to PVP-I
alone were also observed. The outcomes for the PVP-I
group did not show statistical superiority to vehicle, with
the exception of adenoviral eradication at the day 3 visit.
Adenoviral conjunctivitis typically lasts 14-21 days.17 In
our study, the number of patients with complete adenoviral
eradication was significantly higher in the PVP-I/
dexamethasone group than in the vehicle group as early
as the day 3 visit, while the number of patients with both
adenoviral eradication and clinical resolution was signifi-
cantly higher in the PVP-I/dexamethasone group than in
the vehicle group at the day 6 visit. No patients achieved
clinical resolution at the day 3 visit, but at this time point,
70.8% of patients in the PVP-I/dexamethasone group had a
reduction from baseline of >_2 points (out of a maximum to-
tal score of 6) in the global clinical score compared with
39.1% in the vehicle group. A smaller proportion
(35.4%) of patients treated with PVP-I/dexamethasone
demonstrated adenoviral eradication at the day 3 visit,
suggesting that patients receiving this treatment should
be counseled to continue to take precautions for >_6 days
to prevent spread of the infection. Overall, these results
suggest that PVP-I/dexamethasone may be effective at
quickly eradicating the virus and improving clinical signs,
which could benefit quality of life and minimize the spread
of infection. A rapid improvement of conjunctivitis is also
expected to have a positive socioeconomic impact because
patients are able to return to school or work sooner.
PVP-I/dexamethasone appeared to be safe and well
tolerated in this study, with a lower proportion of patients
in the PVP-I/dexamethasone group (53.4%) experiencing
TEAEs than in the vehicle (69%) or PVP-I (62.7%)
groups. There were no serious AEs during the study, no
TEAEs were suspected of being related to study treatment,
and the majority of TEAEs in each treatment group were
mild in severity. In addition, the drop tolerability of
PVP-I 0.6%/dexamethasone 0.1% was acceptable, with
drop comfort scores similar to those in the vehicle group.
This is noteworthy because drop comfort is a component
of ocular tolerability, and ocular discomfort can influence
patient preference and treatment compliance.18
A study that used the adenovirus type 5/New Zealand
rabbit ocular model showed that corticosteroids alone can
increase viral replication and the duration of viral shed-
ding.19 However, results from the present study and
others14–16 suggest that PVP-I/dexamethasone does not in-
crease or prolong viral shedding, with adenoviral eradica-
tion observed from day 3 through day 12 in our study. In
addition, rapid adenoviral eradication and clinical resolu-
tion with PVP-I/dexamethasone should ensure that the
TABLE 3. Ocular Treatment–Emergent Adverse Events Occurring in >_5% of Any Treatment Group (Safety Population)
Event, N (%)
PVP-I/Dexamethasone
N ¼ 58
PVP-I
N ¼ 59
Vehicle
N ¼ 58
All Patients
N ¼ 175
Corneal infiltrates 11 (19.0) 18 (30.5) 12 (20.7) 41 (23.4)
Punctate keratitis 13 (22.4) 16 (27.1) 11 (19.0) 40 (22.9)
Eyelid edema 7 (12.1) 16 (27.1) 12 (20.7) 35 (20.0)
Conjunctivitis 5 (8.6) 10 (16.9) 11 (19.0) 26 (14.9)
Conjunctivitis viral 6 (10.3) 4 (6.8) 6 (10.3) 16 (9.1)
Conjunctival edema 2 (3.4) 4 (6.8) 9 (15.5) 15 (8.6)
Conjunctival disorder 1 (1.7) 6 (10.2) 4 (6.9) 11 (6.3)
Visual acuity reduced 2 (3.4) 5 (8.5) 4 (6.9) 11 (6.3)
Conjunctival follicles 3 (5.2) 5 (8.5) 3 (5.2) 11 (6.3)
Keratitis 2 (3.4) 1 (1.7) 3 (5.2) 6 (3.4)
Eye pain 2 (3.4) 0 4 (6.9) 6 (3.4)
Meibomian gland dysfunction 3 (5.2) 0 2 (3.4) 5 (2.9)
PVP-I ¼ povidone-iodine.
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duration of treatment is short, thus lowering the risk of
steroid-related side effects. Overall, the PVP-I/
dexamethasone antiseptic-steroid combination appears to
have a virucidal effect and also mitigates the secondary im-
mune response (which can lead to more serious ocular
sequelae), thereby accelerating the resolution of associated
clinical signs.
The differential diagnosis of conjunctivitis can be diffi-
cult because different forms of the condition (bacterial,
viral, allergic) present similar symptoms.20 Misdiagnosis
of bacterial conjunctivitis can occur in up to 50% of
cases,21 which often results in inappropriate antibiotic
treatment. PVP-I has broad-spectrum antimicrobial action
that includes bacteria, viruses, and fungi.22 Bactericidal ac-
tivity has been demonstrated in vitro for PVP-I alone10,23
and for PVP-I 0.4%/dexamethasone 0.1%, which in 1 study
killed 99.9% of common ocular pathogens (methicillin-
resistant Staphylococcus aureus, Pseudomonas aeruginosa,
Serratia marcescens, andCandida albicans) within 15 seconds
of exposure.24 PVP-I/dexamethasone therefore has the po-
tential to mitigate the negative effects of misdiagnosis. In
addition, PVP-I/dexamethasone could avoid unnecessary
use of antibiotics and reduce the potential of developing
antibiotic resistance,25,26 which has not been observed
following multiple topical applications of PVP-I alone.27
Infectious conjunctivitis caused by herpes simplex virus
(HSV) is also difficult to differentiate from adenoviral
conjunctivitis.28 Although less common than adenovirus,
HSV keratitis is the most common cause of infectious
corneal blindness in developed countries.28 PVP-I has
been demonstrated in vitro to have virucidal activity
against HSV at concentrations as low as 0.1%.23,29 This
study provides useful data on the efficacy and safety of
PVP-I/dexamethasone, especially since there are few
published results from randomized controlled trials of
topical drug therapies for adenoviral conjunctivitis. The re-
sults from our study are consistent with results from studies
of different PVP-I/dexamethasone formulations.13–16 A
phase 2 pilot study (NCT01461954) conducted in Brazil
has also investigated the safety and efficacy of PVP-I
0.6%/dexamethasone 0.1% compared with vehicle for the
treatment of clinically suspected acute viral conjunctivitis,
and showed trends toward efficacy; however, too few pa-
tients with confirmed adenoviral conjunctivitis were
enrolled to deliver meaningful results.
A strength of our study is that viral culture was used to
confirm infection with adenovirus. A limitation of this
study is that it was conducted only in adults; further
studies are needed to evaluate the safety and efficacy of
PVP-I/dexamethasone in children. As this was a single-
country study, future studies are needed in other popula-
tions and regions and on a broader range of adenoviral
serotypes.
In conclusion, these findings suggest that PVP-I 0.6%/
dexamethasone 0.1% is a promising option for the treatment
of acute adenoviral conjunctivitis. Phase 3 studies are
ongoing to further evaluate PVP-I/dexamethasone for the
treatment of adenoviral conjunctivitis (NCT02998541 and
NCT02998554), and for the treatment of bacterial conjunc-
tivitis (NCT03004924). The advantages of PVP-I/
dexamethasone could include mitigation of the negative
effects of misdiagnosis and consequent reduction of the costs
and risks associated with unnecessary antibiotic
prescriptions.
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